Circulating cytokines in Alzheimer's disease
References (15)
- et al.
The participation of interleukin-6 in the pathogenesis of Alzheimer's disease
Research in Immunology
(1992) - et al.
Elevated circulating tumor necrosis factor levels in Alzheimer's disease
Neuroscience Letters
(1991) - et al.
Correlation of cytokine secretion by mononuclear cells of Alzheimer' disease and disease stage
Journal of Neuroimmunology
(1994) Plasma increase of interleukin-12 and interferon-gamma: pathological significance in autism
Journal of Neuroimmunology
(1996)- et al.
Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children
Clinical and Immunological Immunopathology
(1991) Interleukin-12 and its role in the generation of TH1 cells
Immunology Today
(1993)- et al.
Reduced natural killer cell activity in patients with dementia of the Alzheimer's type
Acta Neurologica Scandinavica
(1991)
Cited by (152)
Genetics of frailty: A longevity perspective
2020, Translational ResearchPrecision pharmacology for Alzheimer's disease
2018, Pharmacological ResearchVisceral adiposity predicts subclinical white matter hyperintensities in middle-aged adults
2017, Obesity Research and Clinical PracticeCitation Excerpt :Making matters worse, these adipocytokines can cross the blood–brain barrier and affect the central nervous system [39,40]. Cross-sectional studies have shown proinflammatory cytokines are elevated in individuals with obesity, and play a role in dementia related neurodegeneration [41,42]. Further, in a cross-sectional study observing the role of inflammation and cognition in an elderly sample, increased IL-6 and C reactive protein correlated to increased cognitive decline [43].
No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease
2016, Experimental GerontologyCitation Excerpt :In a prospective cohort study of patients with mild to severe AD, high baseline levels of TNF-α were associated with an increase in the rate of cognitive decline (Holmes et al., 2009). In addition, increased peripheral levels of IL-6 have been reported in patients with AD in various studies (Singh and Guthikonda, 1997; Licastro et al., 2000). However, in a longitudinal study with a small sample, no significant differences were observed between AD subjects and controls with respect to the mean serum levels of IL-1β, IL-1 receptor antagonist, IL-6, TNF-α, the soluble TNF receptors types I and II, and alpha 1-antichymotrypsin (Lanzrein et al., 1998).
Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease
2016, Neurochemistry International